RPAM
OLMA icon

Rhenman & Partners Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500,000
Closed -$2.13M – 92
2022
Q1 		$2.13M Hold
500,000
– – 0.21% 86
2021
Q4 		$4.7M Buy
+500,000
New +$10.4M 0.31% 76

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rhenman & Partners Asset Management's OLMA Position: Q2 2022 in Review

Rhenman & Partners Asset Management sold out of Olema Pharmaceuticals (OLMA) in Q2 2022, closing a stake of 500,000 shares — an estimated $2.13M sold.

Rhenman & Partners Asset Management first reported a position in OLMA in Q4 2021 and held it in 2 quarters. The position peaked at $4.7M in Q4 2021. 76 funds tracked by Wall St. Rank hold OLMA as of Q2 2022.

  • Rhenman & Partners Asset Management reported no remaining Olema Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 500,000 Olema Pharmaceuticals shares in Q2 2022, an estimated $2.13M.
  • Rhenman & Partners Asset Management first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Olema Pharmaceuticals position peaked at $4.7M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.